Caucasians comprise 4 in 5 of available genomic sequences for analysis. This data is way too homogeneous. Know more about the problem arising out of this limited diversity and what Anuva is doing about it.
Diversity is indispensable to unlock the potential of genomics. However, researchers need far more than just sequence data. Anuva’s Genomic Bio/Data Bank empowers them to create new knowledge not possible with DNA sequence data alone.
Collecting genomic data from diverse populations as well as blending it with data on disease traits to create richer interpretation are both specializations in themselves. Rather than work on data, can drug discovery teams get a partner who can provide what they need?
As the science community embarks on a genomics-led revolution in drug discovery and development, it is helpful to take a bird’s-eye view of where we stand now.
Is genomics in drug discovery and development proven? Read about the impact of genomics on drug discovery and development.
Dr. Jonathan Picker is the Chief Executive Officer of Anuva. He is an affiliate faculty member and clinical geneticist at Boston's Children's Hospital, Harvard Medical School.
With 25 years of experience in Pediatrics and Genetics, Dr. Picker specializes in the interface of clinical care and applied genetic and genomic research. Dr. Picker's research spans diagnostic tools in genetics to descriptive analysis of rare disorders to molecular neuroscience. He was the co-founder and Director of the first Pediatric Pharmacogenomic clinic in the USA; as well as Director of the Harvard Medical School Advanced Human Genetics Training Program Course.
Dr. Picker is the recipient of various prestigious awards, including the first Sidney R. Baer Jr. Prize for Mental health Research. He has authored numerous research papers involving informative cases, molecular biology, behavioral neuroscience, applied clinical genetic guidelines as well as invited reviews and chapters.
Dr. Picker holds a bachelor's degree of Medical Biology in Genetics, and an MBChB in Medicine from Aberdeen University, UK. He also holds an MS in Genetics and Biochemistry and a PhD in Molecular Biology from Newcastle University, UK.
Kushagra Sharma is the President and a Board Member at Anuva. A seasoned business leader with a career spanning entrepreneurship as well as general management, Kushagra has deep expertise in developing and executing business plans in start-ups as well as large corporations. He is responsible for the revenue growth of the business, strategic planning, and partnerships at Anuva.
Before joining Anuva, he was responsible for the strategy and project execution in launching 4G digital services for Reliance Jio in India. Kushagra has previously served in leadership roles in companies like British Telecom, MTS Sistema Shyam, Grail Research and Evalueserve.
He holds a bachelor's degree from Indian Institute of Technology, Delhi and an MBA from INSEAD, Fontainebleau.
Dr. Asmi Shah is the Vice President of Data and Technology at Anuva. She joined Anuva in its very initial years and has contributed significantly in shaping its products end to end along with other R&D platforms. She brings her data science expertise in dealing with big data, managing and standardizing multidisciplinary large scale biological datasets in the field of drug discovery through genomics and phenomics.
Before joining Anuva, she contributed to the research of drug discovery done with the use of high content/throughput screening on various zebrafish assays at University of Heidelberg in Germany and at Harvard Medical School, USA. She has also taken up various technical roles in product management and software R&D with different corporate industries such as Intel, Rambus and Inform Technologies in the USA and with data analytics startups in India.
Dr Shah holds a bachelor’s degree from Saurashtra University, India, an MS from San Jose State University, USA and has pursued her PhD from University of Heidelberg, Germany under a Marie Curie fellowship.
Dr Nick England is the Vice President of Bioinformatics at Anuva. He brings with him over 10 years of commercial bioinformatics experience. He is responsible for the development of bespoke bioinformatics software and pipelines to maximize biological insight from our data.
Before joining Anuva, he worked at Kymab where he developed the bioinformatics used in IntelliSelect for processing and visualizing antibodies from humanized mice, as well as implementing continuous integration and shifting computation to the cloud. This successful informatics platform is now also used by other companies such as LifeArc and Petmedix. He has previously worked on cheminformatics projects with Unilever and Novartis.
Dr England holds an MSci degree in Natural Sciences as well as a PhD in cheminformatics from the University of Cambridge.